

Dan Zuckerman, MD, FASCO

Physician Leadership and Work Experience

<i>Years</i>	<i>Position</i>
07/2024 – present	Co-Director, Oncology Research St. Luke's Cancer Institute, Boise, ID
	<ul style="list-style-type: none">• Serve as PI cooperative group clinical trials through NCORP• Liaison with pharma for selection of solid tumor trials• Coordinate with cellular therapy/heme malignancy team for leukemia/lymphoma trials• Collaborate with other service lines for research best practices
12/2021 – present	Director, GI Oncology St. Luke's Cancer Institute, Boise, ID
	<ul style="list-style-type: none">• Develop and implement clinical pathways in GI cancers• Serve as PI for all GI cancer clinical trials• Serve as liaison to the community gastroenterologists• Coordinate with IR for liver-directed therapies in GI cancers• Oversee clinical content and library for the GI multidisciplinary tumor board
10/2013 – 9/2021	System Medical Director St. Luke's Cancer Institute (formerly MSTI), Boise, ID

Major Responsibilities:

- Served as senior physician leader for the cancer institute, which includes 8 locations and provides cancer care to 70% of our market area and 40% of all patients in Idaho.
- Mentored and supervised site medical directors and 35 staff physicians.
- Served as the spokesperson and face of the cancer institute for TV, radio, digital media and community events.
- Advised St. Luke's Health Partners, our network partner, on designing value-based contracts in oncology.
- Re-designed and negotiated physician compensation, with a shift from standard wRVUs to contracts that pay for quality, value and teamwork with NP/PAs.
- Fundraised in collaboration with the St. Luke's Foundation.

Significant Accomplishments:

- Increased gross patient revenues 70%, from \$230M in FY13 to \$400M in FY20.
- Increased new patient volumes by 40%, from 2900 patients in 2013 to 4100 in 2019.
- Implemented an early, embedded palliative care program, with automatic referral for all patients with advanced cancer and estimated lifespan of 6-24 months.
- Expanded our BMT program by starting pediatric autologous transplants in 2015 and adult allogeneic stem cell transplants in 2018, making us one of the few allo programs in the country outside of an academic center.
- Transitioned to e-consultation workflow for benign hematology, to reduce unnecessary face-to-face visits and lab ordering and to improve access for oncology patients.
- Supported October 2017 go-live of Epic across the entire St. Luke's Cancer Institute

06/2008 – present Staff Medical Oncologist/Hematologist
St. Luke's Cancer Institute, Boise, ID

Postgraduate Medical Education

<i>Years</i>	<i>Position/Program</i>
07/2005 – 06/2008	Fellow in Medical Oncology and Hematology Dana-Farber/Partners Cancer Care, Boston, MA
07/2002 – 06/2005	Intern and Resident in Internal Medicine Brigham and Women's Hospital Internal Medicine Residency Program, Boston, MA

Education

<i>Years</i>	<i>Degree</i>	<i>Institution/Program</i>
09/1998 – 06/2002	M.D.	University of Chicago Pritzker School of Medicine, Chicago, IL Cum laude, Alpha Omega Alpha
09/1993 – 06/1997	B.A.	Williams College, Williamstown, MA Summa cum Laude, Phi Beta Kappa

Professional Activities

2024-2026	Member, Annual Meeting Cancer Care Delivery Track, ASCO
2024	Member, Defining Community Oncologist <i>ad hoc</i> Committee, ASCO
2022-2025	Member, Nominating Committee, ASCO
2022-2024	Member, Rural Task Force, ASCO
2018-2020	Member, Gastrointestinal Cancers Measures Panel, ASCO
2015-2020	President, Idaho Society of Clinical Oncology
2015-2016	Chair, Clinical Practice Committee, ASCO
2012-2017	Member, Payment Reform Workgroup, ASCO
2012-2015	Member, Quality of Care Committee, ASCO
2010-2013, 2015-18	Member, Clinical Practice Committee, ASCO
2009-2010	Member, Guideline Committee on the Use of Bone-Modifying Agents in Metastatic Breast Cancer, ASCO
2007-2009	Member, Advisory Board, <i>American Journal of Hematology/Oncology</i>
2006-2008	Member, Oncology Training Programs Committee, ASCO

Additional Coursework

<i>Years</i>	<i>Institution/Program</i>
2006	Program in Clinical Effectiveness Brigham & Women's Hospital & Harvard School of Public Health Boston, MA

Hospital Appointments

<i>Years</i>	<i>Position</i>
2008 –	Physician, St. Luke's Cancer Institute (formerly MSTI), Boise, ID

Board Certification

<i>Years</i>	<i>Board</i>
2008 –	Medical Oncology, American Board of Internal Medicine
2008 –	Hematology, American Board of Internal Medicine
2005 –	Internal Medicine, American Board of Internal Medicine

LICENSURE AND CERTIFICATION

2008, re-certified 2018	Certification in Medical Oncology and Hematology , ABIM
2015, re-certified 2015	Certification in Internal Medicine , ABIM
2007-present	Physician , State of Idaho
2005-2008	Physician , State of Massachusetts

EDITORIAL BOARDS

2010	<i>Ad hoc</i> reviewer, <i>The Oncologist</i>
2008	<i>Ad hoc</i> reviewer, <i>Journal of Neurological Sciences</i>
2006-2007	Peer reviewer, Medical Oncology Self Evaluation Program 1 st Ed., ASCO

PUBLICATIONS

- 2024 Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, **Zuckerman D**, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM. Adjuvant Trastuzumab Emtansine versus Paclitaxel Plus Trastuzumab for Stage I HER2-Positive Breast Cancer: 5-Year Results and Correlative Analyses from ATEMPT. *J Clin Oncol*. 2024;42:3652-3665.
- 2022 Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, **Zuckerman D**, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. *NPJ Breast Cancer*. 2022;16:18.
- 2021 Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, **Zuckerman D**, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine versus Paclitaxel in Combination with
-

Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. *J Clin Oncol*. 2021;20:2375-2385

- 2021 Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, **Zuckerman DS**, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolane SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ad-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH). *Breast Cancer Res Treat*. 2021;189:103-110
- 2020 Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Bullock AJ, Allen J, **Zuckerman D**, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, Meyerhardt JA. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. *Cancers*. 2020;12:3451.
- 2019 **Zuckerman DS**. Cancer centers hitting the target: we are precise, but are we accurate? *J Oncol Pract*. 2019;16:305-306.
- 2019 Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, **Zuckerman D**, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Koumioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. *JAMA*. 2019;321:1370-1379.
- 2017 Neuss M, Rocque G, **Zuckerman D**, Chiang A, Katta S, Wollins D, Kamin D, Edge S. Establishing a core set of performance measures to improve value in cancer care: ASCO consensus conference recommendation report. *J Oncol Pract*. 2017;13:e135-140.
- 2015 Kalis JA, Pence SJ, Mancini RS, **Zuckerman DS**, Ineck JR. Prevalence of off-label use of oral oncolytics at a community cancer center. *J Oncol Pract*. 2015;11:e139-43.
- 2014 Rosales AR, Byrne D, Burnham C, Watts L, Clifford K, **Zuckerman DS**, Beck T. Comprehensive survivorship care with cost and revenue analysis. *J Oncol Pract*. 2014;10:e81-5.
- 2011 van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann S, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, **Zuckerman DS**, von Roenn JH. ASCO Clinical Practice Guideline Update on the Role of Bone Modifying Agents in Metastatic Breast Cancer. *J Clin Oncol*. 2011;29:1221-1227.
- 2010 Lee AI, **Zuckerman DS**, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberger DS, Hochberg EP. Surveillance imaging of Hodgkin lymphoma in patients in first remission: a clinical and economic analysis. *Cancer*. 2010;116:3835-3842.
-

- 2009 Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, **Zuckerman DS**, Sohani AR. Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. *J Hematopathology*. 2009;20:237-244.
- 2008 **Zuckerman DS**, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. *Cancer*. 2008;112:1879-1891.
- 2008 **Zuckerman DS**, Ryan DP. Adjuvant therapy for pancreatic cancer: A review. *Cancer*. 2008;112:243-249.
- 2008 Eder JP, **Zuckerman DS**. Endpoints for the determination of efficacy of antiangiogenic agents in clinical trials. In: Teicher, BA, Ellis, LM. *Antiangiogenic Agents in Cancer Therapy*, 2nd ed. New Jersey: Humana Press, 2008:509-524.
- 2008 **Zuckerman D**, Chabner BA. Topoisomerase inhibitors: camptothecins, anthracyclines, etoposide. In: Chabner BA, Lynch TJ, Longo DL. *Harrison's Manual of Oncology*, 1st ed. New York: McGraw-Hill, 2008:35-48.
- 2007 Schneeweiss S, Robicsek A, Scranton R, **Zuckerman D**, Solomon DH. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. *J Clin Epidemiol*. 2007;60:397-409.
- 2006 **Zuckerman D**, Hochberg E. Review of durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab. *Clin Adv Hematol Oncol*. 2006;4:442-443.
- 2006 **Zuckerman D**, Seliem R, Hochberg E. Intravascular lymphoma: the oncologist's "great imitator." *Oncologist*. 2006;11:496-502.
- 2006 Penson RT, Kyriakou H, **Zuckerman D**, Chabner BA, Lynch TJ. Teams: communication in multidisciplinary care. *Oncologist*. 2006;11:520-526.

ABSTRACTS

- 2012 Mancini R, Clifford K, Brown M, Watts L, **Zuckerman DS**, Levin R, Robenstein V. Medication therapy management (MTM) in a multidisciplinary supportive oncology clinic. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 30)
- 2012 Rosales, A, Clifford K, Brown M, Watts L, Burnham C, Thomas N, Graves J, Thurston N, Byrne D, **Zuckerman DS**. Comprehensive and financially sustainable survivorship care. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 32)
- 2012 Mancini R, Wilson D, Modlin J, **Zuckerman DS**, Powell C, Rapp D, Collins J, Hutchinson T. Oral chemotherapy: A focus on interventions and access. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 44)
- 2012 Keep K, Shaw A, Leavell S, Wimmer P, Bartholomeus A, Furniss S, Haney C, Condit G, Milburn B, Doshier MA, Zuckerman N, Beck TM, **Zuckerman DS**. Patient-reported outcomes on integrative therapies for pain, tension, and level of comfort. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 58)
- 2012 Clifford K, Tallen C, Davis MH, Griess T, **Zuckerman DS**, Padgett L. Implementing patient-center care: Challenges in community oncology. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 192)
- 2012 Eichmeyer J, **Zuckerman DS**, Beck TM, Camilo N, Sproat P, Burnham C. The value of a genetic counselor for patient identification. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 97)
-

- 2012 Watts L, Camilo N, Thurston N, Betts M, **Zuckerman DS**. Distress management in a community oncology center. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 107)
- 2012 Darland S, Burnham C, Camilo N, Beck TM, **Zuckerman DS**. Driving performance improvement using ASCO's Quality Oncology Practice Initiative (QOPI). *ASCO Quality Symposium*. 2012 (suppl 34; abstr 203)
- 2012 Eichmeyer J, **Zuckerman DS**, Beck TM, Camilo N, Mark K, Barbera J, Bradshaw N, Greenburg B, Johnson D. Telehealth for oncology genetic counseling: An Idaho experience. *ASCO Quality Symposium*. 2012 (suppl 34; abstr 288)
- 2007 **Zuckerman D**, Jacobsen E, LaCasce A, Takvorian T, Hochberg E. High false positive rate with the use of CT and FDG-PET in post-remission surveillance for Hodgkin lymphoma. *49th Annual Meeting of the American Society of Hematology*. Atlanta, Georgia, December 8-11, 2007
-